EUVIMEDEUVIMED entdecken
Crossref

Sarcopenia Frequency Among a Sample of Iraqi COVID-19 Survivors/ A Single Center Study

Reem A. Hammadi, Nizar A. Jasim

Iraqi Journal of Medical Sciences · 18.06.2026 · 24 (1) · 23-34

DOI: 10.22578/snk7p657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iraqi Journal of Medical Sciences, online erschienen am 18.06.2026. Verfasst von Reem A. Hammadi und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Coronavirus disease 2019 (COVID-19) induced by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had a massive negative impact of the healthcare systems worldwide, most obvious in its acute stage, but subtler chronic sequelae are being recognized. Sarcopenia, a progressive loss of muscle mass and strength, is believed to be both a risk factor and a complication of acute COVID-19 in various settings.

Objective

To assess sarcopenia frequency following COVID-19 infection in a sample of Iraqi patients and to study the effect of various patient-related and infection-related factors on its development.

Methods

An observational cross-sectional study, conducted at Baghdad Teaching Hospital in Baghdad, Iraq, from December 2021 until June 2022. A convenience sample of polymerase chain reaction -confirmed COVID-19 infection survivors who were otherwise apparently healthy was recruited, patients’ data were collected by direct questioning with measurements of muscle mass through whole body dual-energy x-ray absorptiometry scan, muscle strength via a hand-held dynamometer and physical performance assessment by 4 meters walking speed to determine sarcopenia category.

Results

The study involved 68 participants (mean age 37.3±11 years). Severe COVID-19 occurred in 12 (17.6%), while 56 (82.4%) had non-severe infection. Sarcopenia was present in 6% (4 patients), probable sarcopenia in 12% (8 patients), with no severe cases. Significant associations were found between sarcopenia and BMI <25 (p=0.023), and between steroid use and probable sarcopenia (p=0.013).

Conclusion

This study shows how common sarcopenia and probable sarcopenia are following COVID-19, 6% and 12% respectively. Having a BMI within the normal range increases the risk of developing sarcopenia and corticosteroid use increases the risk of developing probable sarcopenia.Keywords: COVID-19, sarcopenia, post-COVID.

Zitieren

APA

Hammadi, R. A., & Jasim, N. A. (2026). Sarcopenia Frequency Among a Sample of Iraqi COVID-19 Survivors/ A Single Center Study. Iraqi Journal of Medical Sciences, 24(1), 23-34. https://doi.org/10.22578/snk7p657

Vancouver

Hammadi RA, Jasim NA. Sarcopenia Frequency Among a Sample of Iraqi COVID-19 Survivors/ A Single Center Study. Iraqi Journal of Medical Sciences. 2026;24(1):23-34. doi:10.22578/snk7p657

BibTeX
@article{Hammadi2026,
  author = {Hammadi, Reem A. and Jasim, Nizar A.},
  title = {Sarcopenia Frequency Among a Sample of Iraqi COVID-19 Survivors/ A Single Center Study},
  journal = {Iraqi Journal of Medical Sciences},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {23--34},
  doi = {10.22578/snk7p657}
}
Kostenlos starten →